UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stability of lyophilized teriparatide, PTH(1-34), after reconstitution

European journal of pharmaceutics and biopharmaceutics, 2016-02, Vol.99, p.84-93

2016

Volltextzugriff (PDF)

Abstract P5-08-08: C/EBPβ antagonist peptide, ST101, as a novel therapeutic for breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-08-08

2022

Volltextzugriff (PDF)

Abstract 964: β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activity

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.964-964

2021

Volltextzugriff (PDF)

Abstract 959: C/EBPβ antagonist peptide, ST101, as a therapeutic approach in breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.959-959

2021

Volltextzugriff (PDF)

HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41

Biochemistry (Easton), 1996-10, Vol.35 (42), p.13697-13708

1996

Volltextzugriff (PDF)

Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein β

Molecular cancer therapeutics, 2022-11, Vol.21 (11), p.1632-1644

2022

Volltextzugriff (PDF)

Abstract 2050: Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2050-2050

2019

Volltextzugriff (PDF)

Abstract 1817: C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1817-1817

2020

Volltextzugriff (PDF)

Abstract 1816: β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1816-1816

2020

Volltextzugriff (PDF)

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β

Molecular cancer therapeutics, 2022-11, Vol.21 (11), p.1632-1644

2022

Volltextzugriff (PDF)

DDRE-30. CELL-PENETRATING PEPTIDE ANTAGONIST OF CCAAT/ENHANCER BINDING PROTEIN ß DISPLAYS POTENT ANTI-GLIOBLASTOMA ACTIVITY

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi80-vi81

2021

Volltextzugriff (PDF)

Abstract B149: Anti-tumor and immunostimulatory properties of ST316, a peptide antagonist of beta-catenin for treatment of cancers with aberrant Wnt pathway activity

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.B149-B149

2023

Volltextzugriff (PDF)

Abstract LB016: Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB016-LB016

2023

Volltextzugriff (PDF)

Abstract LB236: ST101, a peptide antagonist of novel I/O target CEBPβ,reprograms MDSCs and promotes an immunoactive tumor microenvironment

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB236-LB236

2023

Volltextzugriff (PDF)

Abstract 3051: JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3051-3051

2024

Volltextzugriff (PDF)

Abstract 5332: ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5332-5332

2024

Volltextzugriff (PDF)

Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2909-2909

2024

Volltextzugriff (PDF)

Abstract LB045: β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB045-LB045

2022

Volltextzugriff (PDF)

Abstract LB206: Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB206-LB206

2022

Volltextzugriff (PDF)

Effect of central-residue replacements on the helical stability of a monomeric peptide

Biochemistry (Easton), 1990-08, Vol.29 (32), p.7511-7515

1990

Volltextzugriff (PDF)

Peptide models of protein folding initiation sites. 2. The G-H turn region of myoglobin acts as a helix stop signal

Biochemistry (Easton), 1993-06, Vol.32 (25), p.6348-6355

1993

Volltextzugriff (PDF)

Peptide models of protein folding initiation sites. 1. Secondary structure formation by peptides corresponding to the G- and H-helices of myoglobin

Biochemistry (Easton), 1993-06, Vol.32 (25), p.6337-6347

1993

Volltextzugriff (PDF)

Folding of peptide fragments comprising the complete sequence of proteins: Models for initiation of protein folding I. Myohemerythrin

Journal of molecular biology, 1992-08, Vol.226 (3), p.795-817

1992

Volltextzugriff (PDF)

Folding propensities of peptide fragments of myoglobin

Protein science, 1997-03, Vol.6 (3), p.706-716

1997

Volltextzugriff (PDF)

Folding of peptide fragments comprising the complete sequence of proteins: Models for initiation of protein folding II. Plastocyanin

Journal of molecular biology, 1992-08, Vol.226 (3), p.819-835

1992

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)
Dissertationen
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Research
(13)
Biochemistry
(12)
Journal Of Molecular Biology
(4)
Molecular Cancer Therapeutics
(3)
Protein Science
(2)
European Journal Of Pharmaceutics And Biopharmaceutics
(1)
Journal Of Biomolecular Nmr
(1)
Neuro-Oncology
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Stability of lyophilized teriparatide, PTH(1-34), after reconstitution

Abstract P5-08-08: C/EBPβ antagonist peptide, ST101, as a novel therapeutic for breast cancer

Abstract 964: β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activity

Abstract 959: C/EBPβ antagonist peptide, ST101, as a therapeutic approach in breast cancer

HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41

Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein β

Abstract 2050: Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo

Abstract 1817: C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activity

Abstract 1816: β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer models

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β

DDRE-30. CELL-PENETRATING PEPTIDE ANTAGONIST OF CCAAT/ENHANCER BINDING PROTEIN ß DISPLAYS POTENT ANTI-GLIOBLASTOMA ACTIVITY

Abstract B149: Anti-tumor and immunostimulatory properties of ST316, a peptide antagonist of beta-catenin for treatment of cancers with aberrant Wnt pathway activity

Abstract LB016: Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin

Abstract LB236: ST101, a peptide antagonist of novel I/O target CEBPβ,reprograms MDSCs and promotes an immunoactive tumor microenvironment

Abstract 3051: JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models

Abstract 5332: ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action

Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms

Abstract LB045: β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity

Abstract LB206: Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model

Effect of central-residue replacements on the helical stability of a monomeric peptide

Peptide models of protein folding initiation sites. 2. The G-H turn region of myoglobin acts as a helix stop signal

Peptide models of protein folding initiation sites. 1. Secondary structure formation by peptides corresponding to the G- and H-helices of myoglobin

Folding of peptide fragments comprising the complete sequence of proteins: Models for initiation of protein folding I. Myohemerythrin

Folding propensities of peptide fragments of myoglobin

Folding of peptide fragments comprising the complete sequence of proteins: Models for initiation of protein folding II. Plastocyanin

Suchergebnisse filtern